Among the more than 100 types of human papillomavirus (HPV), at least 14 are considered as 'high-risk' types which can cause ...

Now, a new vaccine designed to train the body’s immune system to attack this rogue protein is showing promise in early trials ...

Results of a Dana-Farber Cancer Institute-initiated phase 1 clinical trial for patients with melanoma show that an updated ...

F indings from a Phase I trial initiated by Dana-Farber Cancer Institute have demonstrated that the NeoVax personalised cancer vaccine’s updated formula and delivery, NeoVax MI ,is not only feasible ...

A new breast cancer vaccine shows significant promise in preventing and treating the disease, particularly triple-negative ...

A breast cancer vaccine targeting a key protein showed strong immune responses in over 75 percent of its trial participants ...

Results of a Dana-Farber Cancer Institute-initiated phase 1 clinical trial for patients with melanoma show that an updated formula and delivery of the NeoVax personalized cancer vaccine called ...

In this episode presented by Eclipsebio, BioSpace's head of insights Lori Ellis discusses mRNA and srRNA with Andy Geall of ...

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and ...

Although deaths from cancer have gone down over the last couple decades, the disease remains one of the leading causes of death in the United States, just as it has for the last 75 years, according to ...

Researchers say about three-quarters of gastric cancer cases worldwide are caused by the common bacteria Helicobacter pylori ...